Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672775 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
A Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, sponsored by Agensys.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 9
- Study locations
NCT01672775: Completed Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, sponsored by Agensys.
NCT01672775 is a Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology that has completed, run by Agensys. The registered enrollment target is 34 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (88% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01672775, a Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, has completed, sponsored by Agensys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
Conditions Studied
Interventions
- DRUG AGS-16C3F
Study Locations (9)
Michigan
- Site US00005 University of Michigan Medical Center - Ann Arbor
- Site US00003 Karmanos Cancer Institute - Detroit
New York
- Site US00004 Roswell Park Cancer Institute - Buffalo
- Site US00002 Memorial Sloan-Kettering Cancer Center - New York
Washington
- Site US00001 Seattle Cancer Care Alliance - Seattle
Alberta
- Site CA00006 Cross Cancer Institute - Edmonton
British Columbia
- Site CA00008 British Columbia Cancer Agency - Vancouver
Ontario
- Site CA00009 London Health Sciences Centre - London
Quebec
- Site CA00007 Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-07-18 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 1 |
What the finished NCT01672775 record still lists
NCT01672775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which AGS-16C3F is the first listed.
NCT01672775 lists 9 locations in 7 states (Michigan, New York, Washington).
Frequently Asked Questions
What is clinical trial NCT01672775 about?
NCT01672775 is a clinical study titled "A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology". The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
What is the current status of trial NCT01672775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-07-18. Estimated completion is 2017-02-21.
What conditions does trial NCT01672775 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology.
What interventions are being tested in trial NCT01672775?
The interventions under investigation include: AGS-16C3F (DRUG).
Who is sponsoring clinical trial NCT01672775?
This trial is sponsored by Agensys, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01672775 being conducted?
This trial has 9 study locations across Michigan, New York, Washington, Alberta, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01672775's enrollment target sits among peer trials
34 27th of 34 higher than 8 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI